Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis.
György KerekesMonika CzókolyováAttila HamarAnita PusztaiGábor TajtiMónika KatkóEdit VéghZsófia PethőNóra BodnárÁgnes HorváthBoglárka SoósSzilvia SzamosiZsolt HascsiMariann HarangiKatalin HodosiGyörgy PanyiTamás SeresGabriella SzűcsZoltán SzekaneczPublished in: Rheumatology (Oxford, England) (2023)
Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated.